Chiara Gallingani

From regulatory approval to clinical practice: real-world eligibility for anti-amyloid monoclonal antibodies in an Italian dementia-care network

Background: European approval of lecanemab and donanemab has shifted anti-amyloid monoclonal antibodies from trial evidence to health-system implementation. In Italy, reimbursement decisions are pending, and real-world estimates of treatment-ready eligibility under Italian approp...